Clinical management of negative symptoms of schizophrenia: An update.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmacology and Therapeutics

• Publication date

  2015-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.pharmthera.2015.06.008PMID 26116809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Schizophrenia

  2016cited by this paper
• Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain

  2015influential reference
• Altered cingulo-striatal function underlies reward drive deficits in schizophrenia.

  2015cited by this paper
• Psychometric evaluation of the negative syndrome of schizophrenia

  2015cited by this paper
• Pleasure systems in the brain.

  2015cited by this paper
• Using focus groups to design a psychoeducation program for patients with schizophrenia and their family members.

  2014cited by this paper
• A review of reward processing and motivational impairment in schizophrenia.

  2014cited by this paper
• Schizophrenia drug gets negative results for negative symptoms

  2014cited by this paper
• A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia

  2014cited by this paper
• Pregnenolone treatment reduces severity of negative symptoms in recent‐onset schizophrenia: An 8‐week, double‐blind, randomized add‐on two‐center trial

  2014cited by this paper
• Investigation of negative symptoms in schizophrenia with a machine learning text-mining approach

  2014cited by this paper
• Double-blind, randomized sham controlled study of deep-TMS add-on treatment for negative symptoms and cognitive deficits in schizophrenia

  2014cited by this paper
• Combination of escitalopram and aripiprazole causes significant improvement of negative symptoms of simple schizophrenia

  2014cited by this paper
• Defining and measuring negative symptoms of schizophrenia in clinical trials.

  2014cited by this paper
• 113. Maternal inflammation during pregnancy and symptom profiles of offspring diagnosed with schizophrenia

  2014cited by this paper
• Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.

  2014cited by this paper
• The MATISSE Trial–A Critique

  2014cited by this paper
• Preclinical pharmacology of amphetamine: implications for the treatment of neuropsychiatric disorders.

  2014cited by this paper
• Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.

  2014cited by this paper
• Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

  2014cited by this paper
• Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function

  2014cited by this paper
• Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.

  2014influential reference
• Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures.

  2014cited by this paper
• Negative Symptoms in Schizophrenia: An Update on Identification and Treatment

  2014cited by this paper
• Negative, not positive symptoms predict the early therapeutic alliance in cognitive behavioral therapy for psychosis

  2014cited by this paper
• Cognitive-behavioural therapy for schizophrenia in a forensic mental health setting

  2014cited by this paper
• Aripiprazole versus other atypical antipsychotics for schizophrenia.

  2014cited by this paper
• Moderating factors for the effectiveness of group art therapy for schizophrenia: secondary analysis of data from the MATISSE randomised controlled trial

  2014cited by this paper
• Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.

  2014cited by this paper
• The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia: Results From the GIANT Trial

  2014cited by this paper
• Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis.

  2014cited by this paper
• No Effects of Antidepressants on Negative Symptoms in Schizophrenia

  2013cited by this paper
• Escitalopram in the treatment of patients with schizophrenia and obsessive–compulsive disorder: an open-label, prospective study

  2013cited by this paper
• The CAINS: theoretical and practical advances in the assessment of negative symptoms in schizophrenia.

  2013cited by this paper
• N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study

  2013cited by this paper
• Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

  2013cited by this paper
• The evolutionary paradox and the missing heritability of schizophrenia

  2013cited by this paper
• Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia.

  2013cited by this paper
• The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.

  2013cited by this paper
• BCL9 and C9orf5 Are Associated with Negative Symptoms in Schizophrenia: Meta-Analysis of Two Genome-Wide Association Studies

  2013cited by this paper
• The CAINS: theoretical and practical advances in the assessment of negative symptoms in schizophrenia.

  2013cited by this paper
• Pharmacokinetic–pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score

  2013cited by this paper
• Psychoeducational interventions for family members of people with schizophrenia: a mixed-method systematic review.

  2013cited by this paper
• Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases

  2013cited by this paper
• The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia.

  2013cited by this paper
• A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities.

  2013cited by this paper
• A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia

  2013cited by this paper
• Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy.

  2013cited by this paper
• Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways

  2013cited by this paper
• Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making.

  2013cited by this paper
• Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial

  2013cited by this paper
• Extending therapeutic use of psychostimulants: focus on serotonin-1A receptor.

  2013cited by this paper
• Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study

  2013cited by this paper
• Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms.

  2013cited by this paper
• Management of the Negative Symptoms of Schizophrenia

  2012cited by this paper
• Principles of neural sciences

  2012cited by this paper
• Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.

  2012cited by this paper
• Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia.

  2012cited by this paper
• A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia.

  2012cited by this paper
• Association of Catechol‐O‐methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population

  2012cited by this paper
• Prevalence of negative symptoms and associated factors in older adults with schizophrenia spectrum disorder.

  2012cited by this paper
• Cognitive behavior therapy versus other psychosocial treatments for schizophrenia.

  2012cited by this paper
• Dissociation of Hedonic Reaction to Reward and Incentive Motivation in an Animal Model of the Negative Symptoms of Schizophrenia

  2012cited by this paper
• Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).

  2012cited by this paper
• Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?

  2012cited by this paper
• Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

  2012cited by this paper
• Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.

  2012cited by this paper
• Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE).

  2012cited by this paper
• Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale.

  2012cited by this paper
• A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.

  2012cited by this paper
• Augmentation of clozapine with a second antipsychotic – a meta‐analysis

  2012cited by this paper
• Expressed Emotion in Schizophrenia: An Overview

  2012cited by this paper
• Twenty-five years of glutamate in schizophrenia: are we there yet?

  2012cited by this paper
• The state-trait disjunction of anhedonia in schizophrenia: potential affective, cognitive and social-based mechanisms.

  2011cited by this paper
• WITHDRAWN: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia.

  2011cited by this paper
• Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: A meta-analysis of randomized clinical trials

  2011cited by this paper
• Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.

  2011cited by this paper
• Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis.

  2011cited by this paper
• Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.

  2011cited by this paper
• Antiepileptic drugs in the treatment of psychiatric disorders.

  2011cited by this paper
• Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials.

  2011cited by this paper
• The brief negative symptom scale: psychometric properties.

  2011cited by this paper
• Quality of life and its predictors in people with schizophrenia.

  2011cited by this paper
• Treatment-resistant schizophrenia: what's next.

  2011cited by this paper
• A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia

  2011cited by this paper
• Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSS.

  2011cited by this paper
• Psychoeducation for schizophrenia.

  2011cited by this paper
• Psychoeducation for schizophrenia.

  2011cited by this paper
• Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study.

  2011cited by this paper
• Aripiprazole in schizophrenia and schizoaffective disorder: A review.

  2010cited by this paper
• Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis.

  2010cited by this paper
• A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.

  2010cited by this paper
• Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.

  2010cited by this paper
• Cognitive behavioral therapy for schizophrenia.

  2010cited by this paper
• Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia.

  2010cited by this paper
• The Role of Ondansetron in the Treatment of Schizophrenia

  2010cited by this paper
• Beneficial effects of l-arginine on reducing obesity: potential mechanisms and important implications for human health

  2010cited by this paper
• The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training.

  2010cited by this paper
• Functional brain imaging in schizophrenia: selected results and methods.

  2010cited by this paper
• Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.

  2010cited by this paper

• Effect of Probiotics on C-Reactive Protein Levels in Schizophrenia: Evidence from a Systematic Review and Meta-Analysis.

  2025cites this paper
• Effect of n-3 polyunsaturated fatty acids on the treatment of schizophrenia: an updated systematic review and meta-analysis

  2025cites this paper
• Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences

  2025cites this paper
• A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders

  2024cites this paper
• Exploring the impact of biological alterations in the superior thalamic radiations on exploratory eye movements in attenuated psychosis syndrome

  2024cites this paper
• A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia

  2024cites this paper
• Using virtual reality to improve verbal episodic memory in schizophrenia: A proof-of-concept trial

  2024cites this paper
• Add-on Sodium Benzoate and N-Acetylcysteine in Patients With Early Schizophrenia Spectrum Disorder: A Multicenter, Double-Blind, Randomized Placebo-Controlled Feasibility Trial

  2024cites this paper
• Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder

  2024cites this paper
• Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update

  2024cites this paper
• Handling prevents and reverses cognitive deficits induced by sub-chronic phencyclidine in a model of schizophrenia in rats.

  2023cites this paper
• Neurological Soft Signs in Schizophrenia, a Picture of the Knowledge in the Last Decade: A Scoping Review

  2023cites this paper
• Oscillatory Deficits in the Sub-Chronic PCP Rat Model for Schizophrenia Are Reversed by mGlu5 Receptor-Positive Allosteric Modulators VU0409551 and VU0360172

  2023cites this paper
• Handling prevents and reverses cognitive deficits induced by sub-chronic phencyclidine in a model for schizophrenia in rats

  2023cites this paper
• BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling “Negative-Like” Symptoms of Schizophrenia

  2022cites this paper
• Association between motivation and engagement with changes in cognition and symptoms after digital cognitive training in schizophrenia.

  2022cites this paper
• Negative symptom dimensions and social functioning in Chinese patients with schizophrenia

  2022cites this paper
• The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia

  2022cites this paper
• Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach.

  2022cites this paper
• A New Treatment Paradigm

  2022cites this paper
• The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia.

  2022cites this paper
• S0033291720002226jra 526..537

  2022cites this paper
• Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)

  2021influential citation
• Intermittent theta burst stimulation of cerebellar vermis enhances fronto-cerebellar resting state functional connectivity in schizophrenia with predominant negative symptoms: A randomized controlled trial.

  2021cites this paper
• The Many Faces of Negative Symptoms in Schizophrenia

  2021cites this paper
• Comparation of the Montreal Cognitive Assessment Score Indonesian Version (MoCA-INA) and the Personal And Social Performance Scale (PSP) Score in Schizophrenic male with Dominant Negative Symptoms and Non-Dominant Negative Symptoms at Mental Hospital Prof. DR. M. Ildrem Medan

  2021cites this paper
• The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses

  2020cites this paper
• Folic Acid and Vitamin B12 Supplementation on Male Patients with Schizophrenia Predominant Negative Symptoms

  2020cites this paper
• Cognitive Enhancement Therapy in Early Schizophrenia: A Qualitative and Quantitative Case Series of Patients’ Experiences

  2020cites this paper
• The role of D3 receptors in the mechanism of action of Cariprazine

  2020cites this paper
• Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.

  2020cites this paper
• Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain

  2020cites this paper
• Examining the Relationship between Intrinsic Drivers of Motivation and Functional Outcomes in a Cross-Section of Individuals with Psychotic Disorders

  2019cites this paper
• The Prevalence of Negative Symptoms Across the Stages of the Psychosis Continuum

  2019cites this paper
• The role of dopamine D3 receptors in the mechanism of action of cariprazine

  2019cites this paper
• Schizophrenia and motherhood

  2019cites this paper
• Perbedaan Rerata Skor The Positive and Negative Syndrome Scale Skala Negatif Antara Laki-Laki dengan Skizofrenia yang Mendapat Pengobatan Risperidon dengan Penambahan Asam Folat dan Vitamin B12 dan yang Hanya Mendapat Pengobatan Risperidon di Rumah Sakit Jiwa Prof.DR. Muhammad Ildrem Medan

  2019influential citation
• Prospective memory in schizophrenia: A meta-analysis of comparative studies.

  2019cites this paper
• Clinical and demographic differences between patients with manic, depressive and schizophrenia‐spectrum psychoses presenting to Early Intervention Services in London

  2019cites this paper
• La reserva cognitiva en el trastorno mental grave

  2019cites this paper
• Dimensional Psychopathology

  2018cites this paper
• Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning.

  2018cites this paper
• Symptom recovery and relationship to structure of corpus callosum in individuals with an 'at risk mental state'.

  2018cites this paper
• Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability

  2018cites this paper
• N‐acetylcysteine attenuates the cuprizone‐induced behavioral changes and oligodendrocyte loss in male C57BL/7 mice via its anti‐inflammation actions

  2018cites this paper
• Identifying the “Therapy Targets” for Treating the Negative Symptoms of Psychosis Using Cognitive Behavioral Therapy

  2018influential citation
• Sadness/Demoralisation and Apathy

  2018cites this paper
• Social cognition and treatment in psychosis

  2018cites this paper
• Are negative symptoms in schizophrenia a distinct therapeutic target?

  2017cites this paper
• Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls

  2017cites this paper
• Negative symptoms across psychotic spectrum disorders

  2017cites this paper
• PDE Inhibitors for the Treatment of Schizophrenia.

  2017cites this paper
• Phosphodiesterases: CNS Functions and Diseases

  2017cites this paper
• The differential effects of neuroleptic drugs and PACAP on the expression of BDNF mRNA and protein in a human glioblastoma cell line.

  2017cites this paper
• Amorcer un traitement antipsychotique en schizophrénie : la situation au Québec de 1998 à 2006

  2017cites this paper
• Migration and Vitamin D in psychotic disorders – A cross sectional study of clinical and cognitive correlates

  2017cites this paper
• Efficacy Towards Negative Symptoms and Safety of Repetitive Transcranial Magnetic Stimulation Treatment for Patients with Schizophrenia: A Systematic Review

  2017cites this paper
• [Initiating an antipsychotic drug treatment for schizophrenia: the situation in Quebec, Canada, from 1998 to 2006].

  2017cites this paper
• The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol.

  2016influential citation
• The efficacy of cerebellar vermal deep high frequency (theta range) repetitive transcranial magnetic stimulation (rTMS) in schizophrenia: A randomized rater blind-sham controlled study.

  2016cites this paper
• Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics

  2016cites this paper
• Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model.

  2016cites this paper
• The role of the ITIH3 rs2535629 variant in antipsychotic response.

  2016cites this paper
• Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.

  2016cites this paper
• Low vitamin D is associated with negative and depressive symptoms in psychotic disorders.

  2016cites this paper
• Évaluation de l'efficacité de la stimulation électrique transcranienne à courant continu sur les symptômes négatifs et les dysfonctions sexuelles dans la schizophrénie

  2016cites this paper
• The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study.

  2016cites this paper
• Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders

  2016cites this paper
• Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders

  2016cites this paper
• Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.

  2016cites this paper
• Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors

  2016cites this paper
• Treating Negative Symptoms in Schizophrenia: an Update

  2016cites this paper
• A novel pipeline for drug discovery in neuropsychiatric disorders using high-content single-cell screening of signalling network responses ex vivo

  2016cites this paper
• Schizophrenia Pharmacology: Past, Present, and Future Targets for Intervention.

  2016cites this paper
• Metacognitive Reflection and Insight Therapy (MERIT) with a Patient with Persistent Negative Symptoms

  2016cites this paper
• [Negative symptoms: which antipsychotics?].

  2015cites this paper
• Cognitive-behavioural therapy for schizophrenia in a forensic mental health setting

  2014cites this paper
• EFFECTIVENESS AND TOLERABILITY OF CORRECTIONAL THERAPY WITH THE PARTIAL DOPAMINE RECEPTOR AGONIST ARIPIPRAZOLE FOR NEUROLEPTIC HYPERPROLACTINEMIA IN PATIENTS WITH SCHIZOPHRENIC SPECTRUM DISORDERS

  year unknowncites this paper